BACKGROUND: Solid organ transplant recipients commonly are infected with hepatitis viruses, are immunosuppressed, and have other potential hepatocellular carcinoma (HCC) risk factors. METHODS: We studied de novo HCC incidence arising after transplant using U.S. registry data (223,660 recipients, 1987-2005). We used proportional hazards regression to identify HCC risk factors and calculated standardized incidence ratios (SIRs) to compare HCC risk with that in the general population. RESULTS: Based on 74 cases reported by transplant centers to the registry, HCC incidence was 6.5 per 100,000 person-years among kidney, heart, and lung (non-liver) recipients and 25 per 100,000 person-years among liver recipients. Hepatocellular carcinoma incidence among non-liver recipients was independently associated with hepatitis B surface antigenemia (hazard ratio [HR] 9.7, 95% confidence interval [CI] 2.8-33), hepatitis C virus (HCV) infection (HR 6.9, 95% CI 2.5-19), and diabetes mellitus (HR 2.8, 95% CI 1.2-6.6). Among liver recipients, HCC incidence was associated with advancing age (P<0.001), male sex (HR 4.6, 95% CI 1.4-16), HCV infection (HR 3.1, 95% CI 1.3-7.2), and diabetes mellitus (HR 2.7, 95% CI 1.2-6.2). Among non-liver recipients, overall HCC incidence was similar to the general population (SIR 0.8) but elevated among those with HCV (3.4) or hepatitis B surface antigenemia (6.5). Hepatocellular carcinoma incidence among liver transplant recipients was elevated overall (SIR 3.4) and especially among those with HCV (5.0) or diabetes mellitus (6.2). CONCLUSIONS: Hepatocellular carcinoma incidence is elevated among liver transplant recipients and subsets of non-liver recipients. These risk factors indicate the need for improved control of viral hepatitis after solid organ transplantation.
BACKGROUND: Solid organ transplant recipients commonly are infected with hepatitis viruses, are immunosuppressed, and have other potential hepatocellular carcinoma (HCC) risk factors. METHODS: We studied de novo HCC incidence arising after transplant using U.S. registry data (223,660 recipients, 1987-2005). We used proportional hazards regression to identify HCC risk factors and calculated standardized incidence ratios (SIRs) to compare HCC risk with that in the general population. RESULTS: Based on 74 cases reported by transplant centers to the registry, HCC incidence was 6.5 per 100,000 person-years among kidney, heart, and lung (non-liver) recipients and 25 per 100,000 person-years among liver recipients. Hepatocellular carcinoma incidence among non-liver recipients was independently associated with hepatitis B surface antigenemia (hazard ratio [HR] 9.7, 95% confidence interval [CI] 2.8-33), hepatitis C virus (HCV) infection (HR 6.9, 95% CI 2.5-19), and diabetes mellitus (HR 2.8, 95% CI 1.2-6.6). Among liver recipients, HCC incidence was associated with advancing age (P<0.001), male sex (HR 4.6, 95% CI 1.4-16), HCV infection (HR 3.1, 95% CI 1.3-7.2), and diabetes mellitus (HR 2.7, 95% CI 1.2-6.2). Among non-liver recipients, overall HCC incidence was similar to the general population (SIR 0.8) but elevated among those with HCV (3.4) or hepatitis B surface antigenemia (6.5). Hepatocellular carcinoma incidence among liver transplant recipients was elevated overall (SIR 3.4) and especially among those with HCV (5.0) or diabetes mellitus (6.2). CONCLUSIONS:Hepatocellular carcinoma incidence is elevated among liver transplant recipients and subsets of non-liver recipients. These risk factors indicate the need for improved control of viral hepatitis after solid organ transplantation.
Authors: Alessandro Grasso; Rosa Stigliano; Filomena Morisco; Hugo Martines; Alberto Quaglia; Amar P Dhillon; David Patch; Brian R Davidson; Keith Rolles; Andrew K Burroughs Journal: Transplantation Date: 2006-06-15 Impact factor: 4.939
Authors: Wolfgang Sieghart; Thorsten Fuereder; Katharina Schmid; Daniel Cejka; Johannes Werzowa; Fritz Wrba; Xiaowei Wang; Diego Gruber; Susanne Rasoul-Rockenschaub; Markus Peck-Radosavljevic; Volker Wacheck Journal: Transplantation Date: 2007-02-27 Impact factor: 4.939
Authors: J Adami; H Gäbel; B Lindelöf; K Ekström; B Rydh; B Glimelius; A Ekbom; H-O Adami; F Granath Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: Jill Koshiol; Karen Pawlish; Marc T Goodman; Katherine A McGlynn; Eric A Engels Journal: Clin Gastroenterol Hepatol Date: 2013-12-19 Impact factor: 11.382
Authors: Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin Journal: JAMA Date: 2011-11-02 Impact factor: 157.335
Authors: E L Yanik; L M Nogueira; L Koch; G Copeland; C F Lynch; K S Pawlish; J L Finch; A R Kahn; B Y Hernandez; D L Segev; R M Pfeiffer; J J Snyder; B L Kasiske; E A Engels Journal: Am J Transplant Date: 2016-05-12 Impact factor: 9.369
Authors: Michael J Pflüger; Max M Maurer; Karl H Hillebrandt; Andreas Andreou; Dominik Geisel; Moritz Schmelzle; Johann Pratschke; Dennis Eurich Journal: J Clin Exp Hepatol Date: 2020-11-25